New combo shows promise in advanced kidney cancer trial
NCT ID NCT02535533
First seen May 14, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tested a combination of two drugs—axitinib and seleniomethionine—in 45 adults with advanced kidney cancer that had spread. The goal was to find the safest dose and see if the combo could shrink tumors. While not a cure, the approach aims to better control the disease in patients who have already tried other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.